The Manufacturers Life Insurance Company Invests $67,000 in Nautilus Biotechnology, Inc. (NASDAQ:NAUT)

The Manufacturers Life Insurance Company purchased a new stake in Nautilus Biotechnology, Inc. (NASDAQ:NAUT) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 23,612 shares of the company’s stock, valued at approximately $67,000.

A number of other hedge funds have also recently bought and sold shares of NAUT. Dimensional Fund Advisors LP raised its position in shares of Nautilus Biotechnology by 19.8% in the 2nd quarter. Dimensional Fund Advisors LP now owns 574,844 shares of the company’s stock valued at $1,345,000 after purchasing an additional 94,908 shares in the last quarter. Renaissance Technologies LLC increased its stake in shares of Nautilus Biotechnology by 11.2% in the second quarter. Renaissance Technologies LLC now owns 140,100 shares of the company’s stock worth $328,000 after buying an additional 14,100 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its holdings in Nautilus Biotechnology by 63.9% in the third quarter. China Universal Asset Management Co. Ltd. now owns 24,121 shares of the company’s stock valued at $69,000 after acquiring an additional 9,404 shares in the last quarter. Finally, SG Americas Securities LLC acquired a new stake in Nautilus Biotechnology in the third quarter valued at $50,000. Institutional investors and hedge funds own 50.71% of the company’s stock.

Nautilus Biotechnology Stock Down 1.0 %

NASDAQ:NAUT opened at $1.98 on Wednesday. The company has a market cap of $248.62 million, a PE ratio of -3.54 and a beta of 1.14. The business’s 50 day moving average is $2.47 and its two-hundred day moving average is $2.54. Nautilus Biotechnology, Inc. has a 52 week low of $1.88 and a 52 week high of $3.45.

Nautilus Biotechnology (NASDAQ:NAUT) last announced its quarterly earnings data on Tuesday, October 29th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.17) by $0.04. During the same period in the prior year, the firm earned ($0.13) EPS. As a group, sell-side analysts expect that Nautilus Biotechnology, Inc. will post -0.57 EPS for the current fiscal year.

Insider Transactions at Nautilus Biotechnology

In related news, VP Mary E. Godwin sold 47,031 shares of the business’s stock in a transaction dated Monday, September 23rd. The shares were sold at an average price of $2.87, for a total transaction of $134,978.97. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders own 40.50% of the company’s stock.

Analysts Set New Price Targets

Separately, The Goldman Sachs Group lowered shares of Nautilus Biotechnology from a “neutral” rating to a “sell” rating and decreased their price objective for the stock from $2.25 to $1.75 in a report on Thursday, December 5th.

About Nautilus Biotechnology

Nautilus Biotechnology, Inc, a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis.